Published 1 year ago • loading... • Updated 1 year ago

A pharmacy benefit manager stopped covering a GLP-1 for obesity. Now there’s a lawsuit

Summary by KIFI

By Deidre McPhillips, CNN (CNN) — A class-action lawsuit has been filed against CVS Caremark over its decision to stop covering Zepbound, Eli Lilly’s blockbuster GLP-1 drug to treat obesity. When the major pharmacy benefit manager informed patients about the change this year, it suggested that there was “another covered medication that’s safe and effective for your condition and may cost less”: namely Wegovy, from Novo Nordisk, with which CVS Ca…

12 Articles

CNN

+11 Reposted by 11 other sources

Lean Left

A pharmacy benefit manager stopped covering a GLP-1 for obesity. Now there’s a lawsuit

A class-action lawsuit has been filed against CVS Caremark over its decision to stop covering Zepbound, Eli Lilly’s blockbuster GLP-1 drug to treat obesity.

1 year ago·Atlanta, United States

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year